Skip to main content

Table 1 Summary of clinical information

From: Screening for aberrantly methylated and differentially expressed genes in nonalcoholic fatty liver disease of hepatocellular carcinoma patients with cirrhosis

 

NAFLD

(n=12)

Non-NAFLD

(n=126)

p-value

Age (years, mean (SD))

61.00 (9.61)

59.10 (12.00)

0.595

Sex = male (%)

6 (50.0)

100 (79.4)

0.052

BMI (kg/m2, mean (SD))

32.18 (6.56)

26.36 (10.75)

0.069

T (%)

  

0.513

 T1

8 (66.7)

73 (58.4)

 

 T2

4 (33.3)

32 (25.6)

 

 T3

0 (0.0)

17 (13.6)

 

 T4

0 (0.0)

3 (2.4)

 

N (%)

  

0.434

 N0

7 (58.3)

93 (74.4)

 

 N1

0 (0.0)

1 (0.8)

 

 NX

5 (41.7)

31 (24.8)

 

M (%)

  

0.386

 M0

7 (58.3)

95 (75.4)

 

 M1

0 (0.0)

1 (0.8)

 

 MX

5 (41.7)

30 (23.8)

 

Stage (%)

  

0.422

 Stage I

6 (60.0)

72 (59.5)

 

 Stage II

4 (40.0)

28 (23.1)

 

 Stage III

0 (0.0)

20 (16.5)

 

 Stage IV

0 (0.0)

1 (0.8)

 
  1. BMI body mass index